![Robert C. Seid](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert C. Seid
Corporate Officer/Principal bei IOMAI CORPORATION
Profil
Robert C.
Seid has been Vice President of Formulations for Iomai Corp.
since August 2005.
Prior to joining Iomai, he was Senior Director of Formulations and Process Development for Wyeth Wyeth Research and Director of Formulation Development for Aviron, Inc. He had over 20 years of experience in directing formulation optimization and characterization of biological products.
Dr. Seid received a BS degree in Chemistry from the University of California, Berkeley and a PhD in Chemistry from Boston University.
Aktive Positionen von Robert C. Seid
Unternehmen | Position | Beginn |
---|---|---|
IOMAI CORPORATION | Corporate Officer/Principal | 01.08.2008 |
Ehemalige bekannte Positionen von Robert C. Seid
Unternehmen | Position | Ende |
---|---|---|
MedImmune Vaccines, Inc.
![]() MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company was founded on April 15, 1992 and is headquartered in Mountain View, CA. | Corporate Officer/Principal | - |
Wyeth Research
![]() Wyeth Research Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The company is based in Cambridge, MA. | Corporate Officer/Principal | - |
Ausbildung von Robert C. Seid
University of California, Berkeley | Undergraduate Degree |
Boston University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Intercell USA, Inc.
![]() Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
Wyeth Research
![]() Wyeth Research Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The company is based in Cambridge, MA. | Commercial Services |
MedImmune Vaccines, Inc.
![]() MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company was founded on April 15, 1992 and is headquartered in Mountain View, CA. | Health Technology |